Researchers at Vanderbilt University Medical Center have found that eating omega-3 fatty acids regularly can result in prevention of colon polyp formation. The 33% reduced risk of colorectal adenomas was seen in women, but not in men.
The new drug, MDV3100, extended overall survival by 4.8 months (P
Four publications on cancer treatment during pregnancy were published last week in the journal Lancet, serving as new treatment guidelines for chemotherapy and surgery in pregnant patients with solid tumors and hematologic malignancies.
The FDA has granted imatinib full approval as an adjuvant treatment following surgical removal of CD117-positive gastrointestinal stromal tumors in adult patients. This comes after results from a phase III trial showed that patients taking imatinib for 36 months had a 5-year overall survival of 92%, compared to 82% for those patients who took the drug for the standard 12 months of treatment.
Initial results of a multicenter trial show that 2 biomarkers, PCA3 and T2-ERG, are found at high levels in prostate cancer compared to noncancerous prostate cells and correlate well with 2 indicators of aggressive prostate cancer, tumor volume and Gleason score.
It is still difficult to gauge the probability that a low-risk prostate cancer patient may be upgraded to a higher prostate cancer stage. Researchers at Vanderbilt University Medical Center have now determined that smaller prostates were more likely to evolve into more serious, aggressive disease.
The US Food and Drug Administration (FDA) announced the approval of vismodegib (Erivedge), for the treatment of advanced basal cell carcinoma, the most common type of skin cancer, for patients who are not eligible for surgery or radiation, and for metastatic disease.
The US Food and Drug Administration (FDA) has approved the angiogenesis blocker axitinib (Inlyta), a twice daily oral drug, as a second-line treatment for patients with advanced renal cell carcinoma.
Metastatic melanomas that harbor the V600E mutation in the BRAF gene respond rapidly to vemurafenib (Zelboraf), the BRAF V600E inhibitor. But While vemurafenib results in a response in about 80% of melanoma patients, the clinical response among CRC patients is not greater than 5%.
Hypermethylation of TFAP2E Gene in Colorectal Cancer Associated With Unresponsiveness to the Chemotherapy Fluorouracil
A study published earlier this month in the New England Journal of Medicine, identifies specific colorectal tumors that are less responsive to chemotherapy. Researchers at the University of Magdeburg show that the hypermethylation of the transcription factor AP-2 epsilon (TFAP2E) gene results in lower expression of the TFAP2E protein and upregulation of the DKK4 gene, a gene which has been previously associated with resistance to the chemotherapy fluorouracil.